Cancer cells often exhibit elevated lipase activity, which supports their increased need for lipids. By inhibiting lipases, these compounds can disrupt the supply of fatty acids that cancer cells rely on for membrane synthesis, energy production, and signaling. This disruption can potentially slow down or halt cancer cell proliferation. Inhibitors of lipoprotein lipase (LPL) and hormone-sensitive lipase (HSL) have shown promise in preclinical studies.
